alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation

Area of Science:

• Oncology
• Radiation Oncology
• Molecular Biology

Background:

• Integrins are crucial cell surface receptors involved in cell adhesion and signaling.
• Alpha6 integrin plays a role in tumor progression and metastasis.
• Ionizing radiation (IR) is a standard treatment for prostate cancer, but tumor resistance can limit its efficacy.

Purpose of the Study:

• To investigate the role of a mutant alpha6 integrin in prostate tumor cell repopulation after fractionated ionizing radiation (IR).
• To determine if inhibiting alpha6 integrin cleavage affects tumor response to IR.

Main Methods:

• Human prostate cancer cells (PC3N) were engineered to express either wild-type (cleavable) alpha6 integrin (PC3N-alpha6-WT) or a mutant (non-cleavable) form (PC3N-alpha6-RR).
• Tumors were treated with fractionated IR (3 Gy x 10 days).
• Tumor growth inhibition (T/C), tumor growth delay (T-C), tumor doubling time (Td), and tumor cell kill (Log(10) cell kill) were analyzed.

Main Results:

• Tumors expressing mutant alpha6 integrin (PC3N-alpha6-RR) showed increased tumor growth inhibition (39.5% vs 36.1%) and tumor growth delay (28.5 days vs 20.5 days) compared to wild-type (PC3N-alpha6-WT).
• Tumor doubling time was significantly longer (10.5 days vs 5.5 days) in the mutant group.
• Tumor cell kill was slightly reduced in the mutant group (Log(10) 0.8 vs 1.1), but overall IR response was altered, indicating impaired tumor repopulation.

Conclusions:

• Impaired alpha6 integrin cleavage in prostate tumors leads to altered responses to ionizing radiation.
• Blocking integrin cleavage in vivo may enhance the efficacy of IR in treating slow-growing, pro-metastatic prostate cancers.